February 13, 2017
Fitch Even partner Kendrew H. Colton was quoted in an article published in this week’s issue of Chemical & Engineering News, a publication of the American Chemical Society.
The article, titled "Dispute Over the Legal Rights to an Anticancer Agent Continues," discusses the ongoing dispute between Scripps Research Institute California and Oncoceutics, Inc., a clinical-stage drug discovery and development company, involving the patent for an anticancer agent.
Ken has been practicing intellectual property law for over 30 years. His primary practice focus is counseling clients on a wide range of IP matters involving established and emerging chemical and biochemical technologies. Ken has been a member of the Chemical & Engineering News Advisory Board since 2012.
IP Alert | Stock Ownership Leads to Vacatur of $2.75B District Court JudgmentAugust 8, 2022
On June 23, in Centripetal Networks v. Cisco Systems, the Federal Circuit vacated judgment of the district court because stock held by the judge's wife violated the recusal statute and was not harmless error. Read more
IP Alert | Rehearing Reverses Earlier Federal Circuit Decision Finding Silence Supported Negative Claim LimitationJuly 6, 2022
On June 21, in Novartis Pharmaceuticals Corporation v. Accord Healthcare, Inc., a reshuffled Federal Circuit panel reversed course on rehearing to find that a negative claim limitation was not supported by silence in the patent's specification. Read more